Related Experiment Videos
An approach to the management of hyperlipoproteinemia
Insights
Reducing high cholesterol with low-density lipoproteins (LDL) lowers heart attack risk. Treatment strategies now focus on identifying the right patients and optimal methods for managing hyperlipoproteinemia.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Elevated plasma cholesterol, particularly low-density lipoproteins (LDL), is linked to increased risk of myocardial infarction and mortality.
- Understanding normal lipid transport via plasma lipoproteins has advanced significantly.
- Lipoprotein particles vary in composition and function, with LDL implicated in atherosclerosis and high-density lipoproteins (HDL) potentially protective.
Purpose of the Study:
- To shift the clinical focus from
- whether to treat
- hyperlipoproteinemia to
- whom to treat
- and
- how best to treat
- .
- To present a systematic approach for managing hyperlipoproteinemia based on current lipoprotein knowledge.
Main Methods:
- Review of recent clinical trial data on cholesterol reduction and cardiovascular outcomes.
- Analysis of the complex mechanisms of normal lipid transport and lipoprotein metabolism.
- Development of a management strategy for hyperlipoproteinemia informed by lipoprotein science.
Main Results:
- Reduction in plasma cholesterol concentrations, specifically LDL, demonstrably decreases myocardial infarction and death risk.
- A sophisticated understanding of lipoprotein function (LDL vs. HDL) has been achieved.
- A systematic management approach can normalize lipoprotein concentrations in most hyperlipoproteinemic patients.
Conclusions:
- The focus in managing dyslipidemia should be on patient selection and treatment optimization.
- Advanced understanding of lipid transport enables effective management strategies for hyperlipoproteinemia.
- Systematic management based on lipoprotein profiles can lead to normalization of plasma lipid levels and reduced cardiovascular risk.
Abstract:
Recent clinical trials indicate that reduction of plasma cholesterol concentrations in individuals with increased levels of low-density lipoproteins reduces their risk of myocardial infarction and death. Therefore, the question of "whether to treat" should be shifted to "whom to treat" and "how best to treat". The understanding of normal lipid transport via the plasma lipoproteins has grown to a sophisticated level over the past 20 years. Plasma cholesterol, required for cellular membrane integrity, and plasma triglycerides, the primary mammalian energy source, are carried in lipoprotein particles that vary in size, density, lipid composition, and apolipoprotein content. Some lipoprotein particles (low-density lipoproteins) play a causal role in the atherosclerotic process, while other particles (high-density lipoproteins) appear to prevent this process. Utilizing this understanding of the plasma lipoproteins, a systematic approach to the management of the patient with hyperlipoproteinemia has been developed which may lead to the normalization of plasma lipoprotein concentrations in the majority of hyperlipoproteinemic patients.